



Improving Outcomes in Patients With High-Risk HR+/HER2- EBC

Keeping the Patient Central

SATURDAY, 10 SEPTEMBER 2022 | 18:30 – 20:00 CEST

7.3.U - URVAL AUDITORIUM, HALL 7, LEVEL 7.3,
PARIS EXPO PORTE DE VERSAILLES, PARIS, FRANCE

A Medscape **LIVE!** EVENT

MODERATOR



Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast
Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology and US Oncology
Dallas, Texas, United States

PANELISTS



Wolfgang Janni, MD, PhD
Medical Director Women's Clinic
Director, Dept of Obst & Gyn
University Hospital Ulm
Ulm, Germany



Sarah Donahue, MPH, NP, AOCNP
Carol Franc Buck Breast Cancer Center
Helen Diller Family Comprehensive
Cancer Center
University of California, San Francisco
San Francisco, California



Miguel Martin, MD, PhD
Professor of Medicine
Head, Medical Oncology Service
Hospital General Universitario
Gregorio Marañón
Universidad Complutense
Madrid, Spain

AGENDA

18:30 – 18:35

Welcome and Introduction
Joyce O'Shaughnessy, MD

18:35 – 19:00

How Would You Assess Risk of Recurrence in This Patient With HR+/HER2- EBC?
Wolfgang Janni, MD, PhD

19:00 – 19:30

Treatment Considerations for Patients With High-Risk HR+/HER2- EBC: What Do the Latest Data Show?
Miguel Martin, MD, PhD

19:30 – 19:55

Keeping the Patient Central: Discussing Adherence and Persistence and the Role of the MDT
Sarah Donahue, MPH, NP, AOCNP

19:55 – 20:00

Concluding Remarks and Audience Q&A
Joyce O'Shaughnessy, MD